NMN Treats Immune Thrombocytopenia by Restoring NAD+ in Macrophages
A phase 1/2 trial finds low-dose oral NMN safely raises platelet counts in steroid-refractory ITP via a novel immunometabolic mechanism.
Summary
Researchers discovered that in immune thrombocytopenia (ITP) — a condition where the immune system destroys platelets — an enzyme called CD38 depletes NAD+ in macrophages, pushing them into an aggressive state that attacks platelets. Supplementing with NMN restores NAD+ levels, reprograms macrophages, and reduces platelet destruction. A small phase 1/2 clinical trial tested 450 mg of oral NMN twice daily for two weeks in 25 adults with hard-to-treat ITP. No serious side effects occurred, immune function appeared preserved, and 20% of patients met the primary platelet-response endpoint. Broader exploratory measures showed 60% achieved meaningful platelet increases during treatment and 52% maintained responses at eight weeks. This positions NMN as a potential non-immunosuppressive treatment for antibody-driven autoimmune diseases.
Detailed Summary
Immune thrombocytopenia (ITP) is an autoimmune disorder in which the body's own immune cells destroy platelets, causing dangerous bleeding risk. Current treatments often rely on broad immunosuppression, which carries significant side effects. This study identifies a precise metabolic mechanism driving the disease and tests a targeted nutritional intervention to correct it.
The research team first uncovered that the enzyme CD38 depletes NAD+ inside macrophages — immune cells that engulf and destroy platelets in ITP. Low NAD+ drives macrophages into an inflammatory M1-like state with elevated Fc gamma receptor I (FcγRI) expression, making them more aggressive at clearing antibody-coated platelets from circulation. Blocking CD38 or supplementing with NMN in mouse models restored NAD+, reprogrammed macrophages, reduced FcγRI, and prevented thrombocytopenia — without impairing the animals' ability to mount normal antibody responses.
Building on this mechanistic foundation, the team conducted a single-arm, open-label phase 1/2 clinical trial enrolling 25 adults with steroid-refractory or steroid-dependent ITP. Participants received 450 mg of oral NMN twice daily for two weeks. No dose-limiting toxicities or serious treatment-related adverse events were observed. Mild adverse events occurred in 12% of patients and minor infections in 8%, while immunoglobulin levels remained stable — suggesting preserved humoral immunity.
For efficacy, 20% of patients met the primary endpoint of platelet counts reaching ≥50 × 10⁹/L within two weeks. Exploratory analyses were more encouraging: 60% achieved platelet counts more than 1.5× their baseline during treatment, and 52% maintained responses through week 8.
These findings establish the CD38-NAD+ axis as an immunometabolic checkpoint in ITP and open a new therapeutic avenue. The main caveats are the small sample size, single-arm design, and reliance on abstract-only data for this summary. Larger randomized trials are needed to confirm efficacy.
Key Findings
- CD38-driven NAD+ depletion in macrophages promotes platelet destruction in ITP via elevated FcγRI expression.
- NMN supplementation restores NAD+, reprograms macrophages, and prevents thrombocytopenia in mouse models.
- 450 mg oral NMN twice daily for 2 weeks was well tolerated with no serious adverse events in 25 patients.
- 20% of patients met the primary platelet-response endpoint; 60% achieved >1.5× baseline platelet counts.
- Humoral immunity appeared preserved, suggesting NMN avoids the broad immunosuppression of standard ITP therapies.
Methodology
This was a single-arm, open-label phase 1/2 trial (NCT06776510) enrolling 25 adults with steroid-refractory or steroid-dependent ITP who received 450 mg oral NMN twice daily for 2 weeks. Primary endpoints were safety/tolerability and platelet response (≥50 × 10⁹/L confirmed by two consecutive measurements). Mechanistic findings were supported by in vitro and mouse model experiments.
Study Limitations
The trial was small (n=25), single-arm, and lacked a placebo control, making it impossible to rule out spontaneous remission or placebo effect. The 20% primary endpoint response rate is modest, though exploratory measures were more promising. This summary is based on the abstract only, as the full paper is not open access.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.